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ABSTRACT
Aim: The development of the gut microbiota occurs primarily during infancy, and growing
evidence has emphasised its positive role and implications for human health. The aim of
this review was to provide essential knowledge about the gut microbiota and to describe
and highlight the importance of the factors that influence the gut microbiota in early life and
their potential harmful effects later in life.
Methods: The European Paediatric Association, the Union of the National European
Paediatric Societies and Associations, convened a panel of independent European experts
to summarise the research on microbiota for general paediatricians. They used PubMed
and the Cochrane Library to identify studies published in English up to June 2018.
Results: A number of clinical conditions can disrupt the development of a stable gut
microbiota. Changes in the microbiome have been documented in many chronic diseases,
mainly immune-mediated gastrointestinal and liver diseases, and distinct patterns have
been associated with each specific disease. The gut microbiota can be positively
modulated with probiotics, prebiotics, synbiotics, paraprobiotics and postbiotics.
Conclusion: Paediatricians can play a key role in preventing harmful events that could
permanently influence the composition and/or function of the gut microbiota. Various
treatment strategies can be used.
INTRODUCTION
The microbial communities hosted by the human gut have
been forged over millions of years of co-evolution with
humans, to achieve a symbiotic relationship leading to
physiological homoeostasis. The gut microbiota has become
a new, fascinating and promising area of research, which
enables us to understand the development of gut functions
and some health disorders and diseases, as well as their
treatment or prevention.
The development of the gut microbiota occurs primarily
during infancy. Evidence regarding the implications of the
gut microbiota in children is increasing, and new insights
have been reported about the development of the micro-
biome during early life. For example, advances in genome
sequencing technology and metagenomic analysis are
increasing our broader understanding of the gut microbiota
and highlighting differences between healthy and diseased
states. Healthcare professionals involved in paediatric care
may find it difficult to interpret the complex data published
in specialised literature. However, this information is of
considerable importance in paediatric practice. Different
definitions have also caused confusion. These include the
interchangeable use of the basic terms microbiome and
Key notes
 The aim of this review was to describe what is already
known about the gut microbiota, by focusing on the
factors that influence its early development and poten-
tial harmful effects later in life.
 Our review showed that changes in the microbiome
have been documented in many chronic diseases,
mainly immune-mediated gastrointestinal and liver
diseases.
 Paediatricians can positively modulate the gut micro-
biota by using probiotics, prebiotics, synbiotics, para-
probiotics and postbiotics.
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microbiota by the medical community and the general
public when they are talking about the local mini-ecosystem
of a collection of microorganisms in the gut.
METHODS
The European Paediatric Association, the Union of the
National European Paediatric Societies and Associations,
convened a panel of eight independent European experts
from five countries to outline the essential elements of the
current knowledge on the gut microbiota that may be useful
for general paediatricians in their practice. The panel was
chosen based on the experts’ scientific profiles and publi-
cation history, and all members were active participants in
the work and activities of the association. The panel held
their first meeting with regard to this review at the 8th
Europaediatrics Congress in Bucharest in June 2017, where
they discussed relevant issues about the definition and
function of the gut microbiota. They decided that a
particular focus of this review would be to highlight the
factors that influence the gut microbiota in early life, as well
as their potential harmful effects in later life, for the benefit
of general paediatricians. Each panel member was respon-
sible for reviewing the literature on a given topic, according
to their specific expertise. They searched for papers
published in English up to June 2018 by using PubMed
and the Cochrane Library. The members then summarised
the relevant findings on their given topic, and the panel
discussed the findings discussed in a series of meetings until
they reached a final consensus.
RESULTS
A microbiological approach to understanding the gut
microbiota
Previously called the gut microflora, the microbial commu-
nities are composed of approximately 1014 bacteria, which
is approximately 10 times the number of cells in the human
body (1). The term gut microbiota refers to the organisms
that comprise the microbial community, while the term
microbiome refers to the collective genomes of the
microbes, including bacteria, bacteriophages, fungi, proto-
zoa and viruses that live inside and on the human body. The
gut microbiota may be considered a human organ that can
be transplanted, and it has its own functions, such as
modulating the expression of genes involved in mucosal
barrier fortification, angiogenesis and postnatal intestinal
maturation of several gut-associated systems (2).
The gut microbiota comprises more than 2000 microbial
species. Its diversity has been revealed by the application of
metagenomics: 16S ribosomal ribonucleic acid gene or
deoxyribonucleic acid (2). Firmicutes and Bacteroidetes are
the two dominant bacterial phyla in most individuals. Other
phyla include Proteobacteria, Actinobacteria, Fusobacteria
and Verrucomicrobia (2). Groups of bacterial families have
been classified into enterotypes on the basis of their
functions. The term enterotype and its definition remain
debated. For example, the classification may be based on
the metabolism of dietary components and the ability to
metabolise drugs. The aim of this classification is to help us
to understand the role of the gut microbiota in health and
disease. Ageing is associated with changes in the diversity of
noncultured species that current laboratory culturing tech-
niques are unable to grow in the laboratory. These are a
greater proportion of Bacteroides, a distinct abundance of
Clostridium clusters, an increased enterobacteria popula-
tion and a lower number of bifidobacteria. The taxonomic
alterations may be due to changes in diets, such as less fibre,
and/or, the increased use of antibiotics with advancing age
(3).
There is no definition of a normal microbiota, since the
bacterial species vary in different groups of individuals. The
vast majority of microbial species give rise to symbiotic
host–bacterial interactions that are fundamental for human
health. Disrupting the development of a stable gut micro-
biota, which is known as dysbiosis, may be associated with
several clinical conditions. These include nosocomial infec-
tions, necrotising enterocolitis in premature infants, inflam-
matory bowel disease, obesity, autoimmune diseases,
allergies or even functional bowel disorders or behavioural
problems.
Factors influencing neonatal intestinal colonisation
Foetal colonisation and prematurity
The sterility of the gut of the foetus in utero has been
challenged by studies that have identified bacteria, bacterial
deoxyribonucleic acid or bacterial products in the meco-
nium, amniotic fluid and placenta. These indicate the
initiation of microbial colonisation from the mother to
offspring (4,5). Therefore, during developmental phases, the
foetus could encounter bacteria in utero that might con-
tribute to establishing the microbiota before delivery. This
prenatal bacterial colonisation of the foetal gut might be a
source of microbial stimulation, providing a primary signal
for the maturation of a balanced postnatal innate and
adaptive immune system. However, studies stating the
existence of this in utero microbiota remain controversial
(3,4). Importantly it has been shown that meconium with
low bacterial diversity has been associated with a more
frequent onset of sepsis in very low birth weight babies (6).
The first and most important phase of normal colonisa-
tion occurs when the newborn foetus passes through the
birth canal and ingests maternal vaginal and faecal
microorganisms. These bacteria proliferate further when
oral feeding is initiated. After 48 hours, the number of
bacteria is already as high as around104–106 colony-form-
ing units per millilitre of intestinal content. However, many
factors can influence this process and they may potentially
impair the establishment of what is known as symbiosis (7)
(Fig. 1).
The pattern of bacterial colonisation in preterm infants
differs from the pattern observed in the healthy gut of full-
term infants during the neonatal period (7). This abnormal
colonisation, which is mostly due to the routine use of
sterile formula and antibiotics in neonatal intensive care
units, could play a central role in feeding intolerance. It
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could also be indicated in the development of necrotising
enterocolitis, which is a severe disease primarily that affects
premature infants and often leads to death or short bowel
syndrome, which requires an extensive bowel resection (6).
Mode of delivery
The microbiota of vaginally delivered infants mirrors the
vaginal and gut microbiota of the mother. Infants delivered
by Caesarean section have reduced bacterial biodiversity,
and colonisation by Bifidobacteria can be delayed by up to
six months, in contrast to vaginally delivered infants (7,8).
Infants delivered by Caesarean section exhibit bacterial
communities composed of prominent genera, such as
Lactobacillus, Prevotella, Escherichia, Bacteroides and
Bifidobacterium. After a Caesarean section, the gut micro-
biota is characterised by a reduced number of Bifidobacte-
ria species. Although vaginally delivered neonates exhibit
individual microbial profiles, these are characterised by
predominant groups, such as Bifidobacterium longum and
Bifidobacterium catenulatum. Dominguez-Bello et al. used
multiplex 16S ribosomal ribonucleic acid gene pyrose-
quencing to characterise the bacterial communities of
mothers and their neonates. Interestingly, they reported
that vaginally delivered infants acquired bacterial commu-
nities that resembled their own mothers’ vaginal microbiota
and that these were dominated by Lactobacillus, Prevotella
or Sneathia spp. In contrast, infants delivered by Caesarean
section harboured bacterial communities similar to those
found on the skin surface and these were dominated by
Staphylococcus, Corynebacterium and Propionibacterium
spp. (8).
Influence of feeding
The mode of oral feeding may influence the composition of
the gut microbiota in infants. Breastfeeding has been
associated with higher diversity, as assessed using the
Shannon index (9). Human milk contains beneficial factors
for the gut microbiota, such as oligosaccharides (10).
Oligosaccharides function as prebiotics, by stimulating the
growth of Bifidobacterium and Lactobacillus species,
thereby selectively altering the microbial composition of
the intestine (10). It is likely that evolutionary selective
pressure has equipped Bifidobacterium longum subsp.
infantis with multiple enzymes to deconstruct human milk
glycans. As a result, this subspecies is able to outcompete
other Bifidobacteria as well as other commensals and
pathogens in the gut lumen of healthy breastfed infants (10).
In formula-fed infants, Enterococci, Bacteroides and Clos-
tridia predominate. When breastfed infants are one month
of age, there is a direct association between the levels of
secretory immunoglobulin A in intestinal secretions and the
number of Bifidobacteria in the gut. Furthermore, the level
of the proinflammatory cytokine interleukin-6 in intestinal
secretions is inversely related to the number of Bifidobac-
terium fragilis organisms in the gut at one month of age. It
has been suggested that human milk oligosaccharides do
not just stimulate Bifidobacterium longum subsp. infantis
proliferation, they also activate important genes involved in
the proinflammatory and anti-inflammatory balance in the
intestinal mucosa (11). These observations provide addi-
tional evidence of the beneficial effects of breastfeeding for
the newborn infant (Fig. 2). In addition to human milk
oligosaccharides, human milk contains other glycans with
antimicrobial and prebiotic activity that are thought to have
beneficial effects on the infant (12). On the other hand,
there is accumulating evidence that human milk is not
sterile, but contains maternally derived bacterial molecular
motifs that are thought to influence the development of the
newborn infant’s immune system (13). This mechanism,
which has been called bacterial imprinting, requires further
research (13). However, comparative studies with formula-
fed infants have not carefully documented the effects of
formula feeding on the gut microbiota or health-promoting
bacteria. There is growing evidence that the microbiota
does not reach its adult composition until two to three years
of age (14). Finally, host defences can be improved by
breastfeeding, which helps the immature intestinal mucosal
immune system to develop and respond appropriately to
highly variable bacterial colonisation and food antigen
loads. Later in life, the type of food consumed influences the
profile of the gut microbiota (15) and short-chain fatty acids
play a central role (16). Short-chain fatty acids are organic
fatty acids that are produced in the distal gut by the
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Figure 1 Role of neonatal bacterial colonization in establishing symbiosis.
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escapes digestion in the upper gastrointestinal tract and
enters the colon. They are central to the physiology and
metabolism of the colon. Resident bacteria can also
metabolise dietary carcinogens, synthesise vitamins and
assist in the absorption of various molecules. Research has
shown that 90-95% the short-chain fatty acids present in
the colon are made up of acetate (60%), propionate (25%)
and butyrate (15%). Butyrate is a major energy source for
the colonic epithelium. Short-chain fatty acids have been
associated with improved metabolic functions in individu-
als with type 2 diabetes mellitus, as they help to control
blood glucose levels, insulin resistance and glucagon-like
peptide-1 secretion (16).
Gut microbiota predators
The use of broad-spectrum antibiotics significantly reduces
the relative abundance of Bacteroidetes and increases the
abundance of Firmicutes at the same time. A reduction in
microbial diversity is often observed in infants under one
year of age who have received oral antibiotics. Complete
recovery of the initial bacterial composition is not always
achieved. The response depends on the type of antibiotics,
the duration of administration and the baseline micro-
biome. Studies have reported that antibiotics that target
specific pathogenic infections and diseases may alter the gut
microbiota ecology, and interactions with the host meta-
bolism, to a much greater degree than previously assumed
(17).
The prolonged use of antibiotics, which is common in
preterm infants, profoundly decreases microbial diversity
and promotes the growth of predominant pathogens, such
as Clostridium, Klebsiella and Veillonella, which have been
associated with neonatal sepsis. It has been suggested that
there may be healthy microbiota present in extremely
premature neonates that may ameliorate the risk of sepsis
(6). More research is needed to determine whether different
antibiotics, probiotics or other novel therapies could re-
establish a healthy microbiome in neonates. It has also been
reported that when low-dose antibiotic exposure disrupted
the microbiota during maturation, this altered the host
metabolism and adiposity in mice (18). A study that gave
mice low-dose penicillin immediately after birth demon-
strated that metabolic alterations and changes in the ileal
expression of genes were involved in immunity (18).
Administering low-dose penicillin sufficiently perturbs the
microbiota to modify body composition, even when these
drugs are limited to early life. This indicates that microbiota
interactions in infancy may be critical determinants of long-
term host metabolic effects.
Other xenobiotics, such as proton pump inhibitors, may
alter the gut microbiota. Meta-analyses have shown that the
use of proton pump inhibitors potentially increased the risk
of enteric infections caused by Clostridium difficile. They
have also led to small intestinal bacterial overgrowth,
spontaneous bacterial peritonitis, community-acquired
pneumonia, hepatic encephalopathy and adverse outcomes
of inflammatory bowel disease (19).
The role the gut microbiota plays in gut maturation
A study by Hooper et al, published in 2001, reported that a
single bacterial species, Bacteroides thetaiotaomicron,
which is a prominent component of normal mouse and
human intestinal microbiomes, modulated the expression of
genes involved in several important intestinal functions.
These included nutrient absorption, mucosal barrier forti-
fication, xenobiotic metabolism, angiogenesis and postnatal
intestinal maturation (20). Another study that covered
gastrointestinal motility, found that bacterial metabolites,
such as short-chain fatty acids and deconjugated bile salts,
generated potent motor responses (21). Colonised mice
have been shown to have a faster intestinal transit time than
germ-free mice (20). Collectively, the gut microbiota influ-
ences tissue regeneration, the permeability of the epithe-
lium, the vascularisation of the gut and tissue homoeostasis.
Role of the gut microbiota in the development of the gut
immune system
The intestine is an important immune organ that harbours
approximately 60% of the total immunoglobulins and more
than 106 lymphocytes per gram of tissue. The largest pool of
Intestinal microbiota
Probiotics Prebiotics




Figure 2 The central role played by Bifidobacterium species in the development of the gut associated immune system.
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immune-competent cells in the body is housed in the
intestinal mucosa. The number of T lymphocytes and
plasmocytes within the intestinal lamina propria increases
markedly in response to intestinal colonisation. Although
immunoglobulin A producing cells are virtually absent in
germ-free mice, high levels are detectable in the mucosa
when bacterial colonisation occurs (22). The gut microbiota
exerts positive stimulatory effects on the intestinal innate
and adaptive immune systems, by modulating the develop-
ment of the intestinal mucous layer and lymphoid struc-
tures, immune-cell differentiation and the production of
immune mediators (23,24). The innate immune system must
discriminate between pathogens and the harmless com-
mensal bacteria of the gut microbiota. Pathogen recognition
receptors, such as Toll-like receptors and nucleotide-bind-
ing oligomerisation domain receptors, enable us to recog-
nise a restricted number of bacterial motifs. These can be
either microbe-associated molecular patterns or, in the case
of pathogens, pathogen-associated molecular patterns (24).
Both types of pathogen recognition receptors are naturally
expressed by the intestinal epithelial and antigen-presenting
cells, such as dendritic cells or macrophages, and this
enables them to sense any bacterial motifs easily. The
intestinal epithelial barrier is protected by a highly viscous
microfilm to avoid permanent and unwanted stimulation of
the innate immune system. This prevents close contact
between the commensal bacteria and intestinal epithelial
cells.
The intestinal mucosal barrier function can be defined as
the capacity of the intestine to host commensal bacteria and
molecules, while preserving the ability to absorb nutrients
and prevent the invasion of host tissues by resident bacteria.
The dense communities of bacteria in the intestine are
separated from body tissues by a monolayer of intestinal
epithelial cells. The assembly of the multiple components of
the intestinal barrier is initiated during foetal development
and continues during early postnatal life. This means that
the intestinal barrier is not completely developed soon after
birth, particularly in preterm infants. The secretion of
mucus-forming mucins, secretory immunoglobulin A and
antimicrobial peptides reinforces the mucosal barrier on the
extra-epithelial side, while a variety of immune cells
contribute to mucosal defence on the inner side. Thus, the
mucosal barrier is physical, biochemical and immune in
nature. In addition, the microbiota may be viewed as part of
this system because of the mutual influence of the host and
the luminal microorganisms.
Altered mucosal barrier function, accompanied by
increased permeability and/or bacterial translocation, has
been linked to a variety of conditions. These have included
metabolic disorders, such as type 2 diabetes mellitus, insulin
resistance, obesity and inflammatory bowel diseases (25).
Genetic and environmental factors may converge to evoke
defective functioning of the barrier, which, in turn, may lead
to overt inflammation of the intestine as a result of an
exacerbated immune reaction towards the microbiota.
Inflammatory bowel diseases may be both precipitated
and treated by either stimulation or downregulation of the
different elements of the mucosal barrier, and the outcome
depends on the timing, the types of cells affected and other
factors. Fermentation products of commensal bacteria have
been shown to enhance the intestinal barrier’s function, by
facilitating the assembly of tight junctions through the
activation of adenosine monophosphate-activated protein
kinases (26). On the other hand, removing the entire
detectable commensal gut microbiota by using a four-week
course of four orally administered antibiotics – vancomycin,
neomycin, metronidazole and ampicillin – led to more
severe intestinal mucosal injury in a mouse colitis model
induced by dextran sulphate sodium (27). Early treatments
with broad-spectrum antibiotics have been shown to alter
the gastrointestinal tract’s gene expression profile and
intestinal barrier development (28). This finding underlines
the importance of normal bacterial colonisation in the
development and maintenance of the intestinal barrier.
Antibiotic therapy between birth and five years of age might
increase the risk of Crohn disease by disrupting the pattern
of gut colonisation (29). A meta-analysis confirmed that
antibiotic use was associated with an increased risk of new-
onset Crohn disease, but not of ulcerative colitis (30).
In summary, the gut microbiota protects against patho-
gens, influences the development of the intestinal barrier
and its functions and plays many roles in the development
of the gut immune system. It acts by competing for nutrients
and receptors, by producing antimicrobial compounds and
by stimulating a multiple-cell signalling process that can
limit the release of virulence factors.
Role of the gut microbiota in health and disease
As emphasised above, microorganisms colonise the human
gut from birth, and even before that, and stimulate the
development of the local and systemic immune systems. In
addition, the newly developed immune system shapes the
gut flora, which means that it is unique for every individual.
An imbalance or alteration in the composition and/or
function of the microbiota, which is usually called dysbiosis,
has been found to be associated with many chronic diseases
(31). However, in this relationship, it is almost impossible to
delineate the causes from the consequences, as few studies
have shown that changes in the microbiota precede
inflammation (31).
Inflammatory bowel disease
The current hypothesis of the aetiology of inflammatory
bowel disease suggests that the inflammation is a conse-
quence of an unrestrained or aberrant immune response to
the gut flora, which is shaped by different environmental
factors in a genetically predisposed individual (32).
The most consistent changes that have been described
have been a reduction in the diversity of the gut microbiota,
increased abundance of Bacteroidetes and Proteobacteria
and the loss of Firmicutes (32). Furthermore, the loss of
certain specific beneficial microbes, such as Faecalibac-
terium prausnitzii and members of Clostridium clusters
XIVa and IV, has previously been described (33). The
importance of these specific microorganisms has been
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further demonstrated by their ability to inhibit inflamma-
tion and affect the differentiation of regulatory T cells. More
precisely, Faecalibacterium prausnitzii has the ability to
stimulate the production of interleukin-10 and inhibit
proinflammatory cytokines such as interleukin-12 and
interferon-gamma. Other mechanisms could also be
involved, such as decreased production of short-chain fatty
acids, which then affects the differentiation and expansion
of regulatory T cells and the growth of epithelial cells.
Another well-described feature of patients with inflam-
matory bowel diseases is altered intestinal barrier function,
and this has mainly been increased permeability and
decreased mucus production. Both of these factors can be
influenced by the microbiota, but they can also give bacteria
easier access to the mucosa, allowing them get closer to
immunocompetent cells. Patients with inflammatory bowel
diseases exhibit increased colonisation by bacteria that are
able to adhere to the intestinal epithelium, causing altered
permeability of the intestine (34). This adherence can be
further promoted by the increased number of mucolytic
bacteria, such Ruminococcus gnavus and Ruminococcus
torques (35). In addition, the number of sulphate-reducing
bacteria, such as Desulfovibrio, is increased in patients with
inflammatory bowel disease. This has been shown to result
in the production of hydrogen sulphate, which damages
intestinal epithelial cells and induces mucosal inflammation
(36).
Functional gastrointestinal disorders
The pathogenesis of functional gastrointestinal disorders
has not yet been fully explained, but the proposed mech-
anisms include mild gastrointestinal inflammation, visceral
hypersensitivity, an altered brain–gut axis and altered gut
microflora (37).
The most notable changes in microbial intestinal coloni-
sation during the first weeks and months of life have been
described in infants with infant colic (38). These infants
were reported to have decreased faecal-bacterial diversity,
increased gram-negative bacterial colonisation and a lack of
Actinobacteria and Firmicutes, which appears to have a
protective effect. More specifically, infants with colic have
been shown to have more Proteobacteria and less Bifi-
dobacteria and Lactobacillus (39). Although a cause versus
effect phenomenon has not been fully described, there is
evidence that changes in the gut microbiota precede the
development of infantile colic (40).
Similar changes in the microbiome have been reported in
older children with functional gastrointestinal disorders.
One meta-analysis, published in 2017, identified downreg-
ulated colonisation of Lactobacillus, Bifidobacterium and
Faecalibacterium prausnitzii in patients with irritable
bowel syndrome, particularly in irritable bowel syndrome
where diarrhoea predominated (41). Furthermore, a greater
proportion of the Proteobacteria phylum and of genera,
such as Dorea, Haemophilus, Ruminococcus and Clostrid-
ium species, were found in the same group of patients, (42).
These changes might have altered or influenced visceral
perception, gut motility, gut permeability and intestinal gas
production, which can lead to functional gastrointestinal
disorders where pain is the predominant complaint.
Allergies
The immune system of the gastrointestinal tract is in close
proximity to many antigens that originate mainly from food
and the gut microbiota, both of which can affect immune
tolerance. The normal commensal microflora play an
essential role in inflammatory homoeostasis and appropri-
ate immune regulation and may therefore influence the
development of allergic diseases. It has been suggested that
alterations in the microbiota can disrupt mucosal immune
tolerance, leading to allergic diseases, such as food allergies,
atopic dermatitis and even asthma (43). The early micro-
biota of children who later developed allergies has been
characterised by lower bacterial diversity, with predomi-
nant Firmicutes, higher counts of the Bacteroidaceae,
increased numbers of the anaerobic Bacteroides fragilis,
Escherichia coli, Clostridium difficile, Bifidobacterium
catenulatum, Bifidobacterium bifidum and Bifidobacterium
longum. In contrast and decreased numbers of Bifidobac-
terium adolescentis, Bifidobacterium bifidum and Lacto-
bacillus have been reported (44). When the microbiota of
children with allergies was assessed at the onset of allergic
symptoms in one study, it showed a different pattern, with
higher counts of Bacteroides, lower counts of Akkermansia
muciniphila, Faecalibacterium prausnitzii and Clostridium
and overall lower bacterial diversity (45).
The potential mechanisms underlying an increased risk of
sensitisation and allergy development, detected as a conse-
quence of dysbiosis in animal models, have been related to
various alterations in mucosal regulatory T cells. Other
reported effects were defects in the epithelial barrier
function, as evidenced by increased mucosal permeability,
diminished secretory immunoglobulin A production and
excretion and altered dendritic and B-cell function (44).
Obesity and liver disease
Studies have shown that gut microbiota could also play an
important role in the etiopathogenesis of obesity and other
prevalent chronic liver diseases, such as nonalcoholic fatty
liver disease and nonalcoholic steatohepatitis.
Nonalcoholic fatty liver disease has become one of the
most frequent causes of liver disease and represents a
spectrum of pathologies, varying from steatosis to nonalco-
holic steatohepatitis, with or without cirrhosis, and possible
evolution to hepatocellular carcinoma. Nonalcoholic fatty
liver disease is a multifactorial disease that is affected by
genetic, metabolic, dietary and environmental factors. The
most commonly proposed theory is the multiple hit
hypothesis, which also involves changes to the gut micro-
biota (46).
The gut microbiota plays an important role in obesity,
and this is primarily based on its influence on energy
balance. Dysbiosis affects short-chain fatty acid production
and metabolism and adipocyte lipid deposition, with a
decrease in mitochondrial fatty acid oxidation. Human
studies have reported that the balance between
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Bacteroidetes and Firmicutes has been related to obesity.
Lean subjects have more Bacteroidetes in their gut micro-
biota, and diet that restricted fats and carbohydrates was
shown to increase the ratio in favour of Bacteroidetes (47).
With regard to chronic liver disease, the proposed
mechanisms for the negative effects of dysbiosis include
small intestine bacterial overgrowth, altered release of
inflammatory cytokines, alteration of the intestinal barrier,
choline metabolism, endogenous ethanol production, reg-
ulation of hepatic toll-like receptors expression in patients
with nonalcoholic fatty liver disease or nonalcoholic
steatohepatitis and an alteration in bile acid metabolism
(48).
Furthermore, there is evidence that gut dysbiosis pro-
motes the progression of nonalcoholic steatohepatitis to
cirrhosis and hepatocellular carcinoma via an increase in
tumour necrosis factor alpha and interleukin-8, the activa-
tion of toll-like receptor-4 and toll-like receptor-9 and the
production of interleukin-1beta in Kupffer cells, favouring
lipid accumulation, hepatocyte death, steatosis, inflamma-
tion and fibrosis (49).
There have been many animal studies that have evaluated
the gut microbiota differences associated with nonalcoholic
fatty liver disease or nonalcoholic steatohepatitis, but few
studies have been performed in humans and they have
produced inconsistent results. Patients with nonalcoholic
steatohepatitis, including children, have been reported to
have lower levels of Bacteroidetes than patients with liver
steatosis or healthy individuals (50). Firmicutes have been
found in higher levels in individuals with nonalcoholic fatty
liver disease than in healthy subjects (51), but the results
have not been consistent (52).
Modulation of the gut microbiota
The gut microbiota can be modulated to achieve health-
promoting effects (53). The beneficial manipulation of the
composition and metabolic footprint of the gut microbiota
can be achieved by using probiotics. These can be defined as
a preparation of, or a product containing, viable microor-
ganisms in an adequate number to enable such dietary
preparations to favourably modulate the gut microbiota
(53,54). The ability to exert a beneficial modulation on the
gut microbiota may be enhanced by combining probiotics
with other ingredients (64), namely prebiotics, which are
capable of favouring the growth and/or activity of microor-
ganisms. Prebiotics appear to be poorly understood by the
general public in this regard (55). It is important to correctly
define, and understand, prebiotics and their potential when
they are combined with probiotics. This information needs
to be disseminated beyond the scientific community, so that
regulatory agencies, the food industry and healthcare
professionals can correctly describe them and suggest how
they should be used. The combined use of prebiotics and
probiotics may be described as synbiotic if the net health
benefit is synergistic and scientifically validated (56).
Finally, the terms paraprobiotic and postbiotic describe
nonviable bacterial cells and soluble factors that are
secreted as metabolic by-products by live bacteria. Such
products, which could also be released after bacterial lysis,
can provide additional physiological benefits to the host
organism. That is why they have received increasing
attention from scientific researchers and industry, due to
their potential food and pharmaceutical applications
(Table 1).
Probiotics
Probiotics have been defined as live microorganisms that,
when administered in adequate amounts, confer a health
benefit on the host (53,57). The term probiotics is used
widely, but not always properly, in the scientific literature
and by the industry. Their fundamental characteristics
have been described extensively in the literature (53),
including their microbial origin, their viability and their
benefit to the health of the host (Table 2). The microbial
origin of a probiotic product must be guaranteed by
identifying a taxonomically defined microbe or combina-
tion of microbes. A probiotic must therefore be properly
identified by strain-genotypically and phenotypically char-
acterised. An essential characteristic of a probiotic is its
viability (57), as it must be a live microorganism that is
able to survive the acidity of the stomach in order to
reach and colonise the intestinal tract. Moreover, a
probiotic must be guaranteed to remain viable and stable
throughout the technical procedures, during its produc-
tion, use and storage.
A consensus statement was issued by the International
Scientific Association for Probiotics and Prebiotics in 2013
with regard to the possible benefits of probiotics to human
health. The statement sought to further clarify the appro-
priate use and scope of the term probiotic and stated that
probiotics should exert specific general benefits, which it
defined as core benefits (58). These benefits include con-
tributing to establishing and sustaining a healthy gut
microbiota. They are expected to be obtained by creating
a favourable intestinal environment through nonstrain-
specific beneficial actions that are shared by most probi-
otics, which sustain a healthy digestive tract and immune
Table 1 Probiotics, prebiotics, synbiotics, paraprobiotics and postbiotics in
clinical practice. Definitions
 Probiotics: Food or food supplements containing viable microrganisms,
able to modify the microflora of their hosts, with potential beneficial
outcomes on their health
 Prebiotics: Food or food supplements containing nondigestible com-
ponents, able to selectively stimulate the activity and, or, growth of
autochthonous bacteria
 Synbiotics: Products containing a combination of probiotics and
prebiotics
 Paraprobiotics: Nonviable, inactivated microbial cells containing prod-
ucts that have shown dose-related beneficial effects in selected groups
of patients
 Postbiotics: Products containing inactivated (nonviable) bacterial
products or metabolic by-products from probiotic microorganisms,
able to exert potentially beneficial biological activity on their hosts
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system. In fact, some effects of probiotics can be observed
across taxonomic groups and are achieved through general
mechanisms, such as the inhibition of pathogens and the
production of beneficial metabolites. These effects should
be distinguished from other benefits, such as neurological or
endocrinological effects, which are strain specific.
An important aspect of probiotic activity is identifying the
adequate amount that is able to confer health benefits on
the host and a specific accepted definition of this is not
currently available. Nevertheless, some regulatory
approaches in Canada and Italy (59,60) have suggested
that a probiotic product should contain at least 1^109
colony-forming units per serving to be able to exert the
claimed beneficial effects.
The 2013 Statement also describes the different cate-
gories of live microorganisms for human use, in order to
distinguish what can and cannot be considered a probiotic,
according to health claims (58). Products claiming to
contain live and active cultures should not be considered
probiotics, because the simple use of the terms live and
active does not imply any probiotic activity. Foods or
supplements that state they contain probiotics have no
specific health claims, and their expected effects are those
related to the core benefits, as demonstrated by well-
conducted human studies. Products containing probiotics
that make specific health claims are those that claim to have
any beneficial health effects, according to documented
evidence from well-designed observational studies. Prod-
ucts containing probiotics that claim they can prevent or
treat a specific disease need to be backed up by appropriate
trials to meet the regulatory standards for drugs.
Probiotics are commonly used in paediatric practice, and
a summary of the indications and limitations is reported in
Table 3. Their use includes preventing common and
nosocomial infections, allergies and antibiotic-associated
diarrhoea, treating acute gastroenteritis and functional
abdominal pain disorders and preventing and treating
infantile colic. Guidelines by Hojsak et al. on using
probiotics in clinical practice for children were published
in 2018 (53), and the study reported that they seemed to be
safe in general, even when provided in high doses. The
authors provided a detailed description of the correct
conditions for their use, together with specific positive
instructions (53) for the use of strictly defined strains for
various clinical conditions. These conditions include
preventing upper respiratory tract infections in children
attending day care centres, nosocomial diarrhoea and
antibiotic-associated diarrhoea and treating acute gastroen-
teritis and infantile colic in breastfed infants.
Prebiotics
The definition of prebiotics has undergone an important
evolution over time. They were initially referred to as nondi-
gestible food ingredients that beneficially affect the host by
selectively stimulating the growth and/or activity of one or a
limited number of bacteria already residing in the colon (S61).
Several studies have focused on the nondigestible oligosac-
charides fructans, namely fructooligosaccharides and inulin,
and galactans, namely galactooligosaccharides, and how they
exert their effects through the enrichment of Lactobacillus
and/or Bifidobacterium spp. (S62).
Prebiotics have been described as nondigestible com-
pounds that confer a beneficial physiological effect on the
host (S63). They do this by metabolising microorganisms
in the gut, which then modulate the composition and/or
activity of the gut microbiota. In 2017, the International
Scientific Association for Probiotics and Prebiotics Con-
sensus Statement proposed a new definition for prebiotics
(S64). The document discussed the concept of selectivity
with respect to fermentation by bacteria and suggested that
prebiotics were defined as substrates that are selectively
utilised by host microorganisms and confer a health
benefit on the host (51) (Table 4). Incorporating the
concept of selectivity in the definition is important, as it
distinguishes between prebiotics and other substances. The
term selective does not mean that only lactobacilli and
bifidobacteria are affected by prebiotics. It means that a
broader range of microorganisms, but not all, can be
affected. Substances that can affect the composition of the
microbiota, but are not selectively used by microorgan-
isms, are not prebiotics.
The use of prebiotics in paediatric clinical practice is
currently limited. Human milk oligosaccharides are a group
of prebiotics that can influence a newborn infant’s gas-
trointestinal health by favouring the development of a
healthy gut microbiota through some metabolic and
immunological activities. It has been demonstrated that
an infant’s consumption of human milk oligosaccharides
increases the proportion of human milk oligosaccharide-
consuming Bifidobacteriaceae, particularly Bifidobacterium
longum subsp. infantis and Bacteroidaceae (S65). The
mechanisms of action in the newborn infant’s intestine
include immune regulation and preventing the adhesion of
pathogens to the intestinal epithelium, which protects the
infant from infections (S66). Some compounds that are
equivalent to human milk oligosaccharides or bovine milk
oligosaccharides are obtained by enzymatic synthesis. It is
still a matter of debate whether these are able to exert
beneficial effects on human health by selectively stimulating
the microbiota and thus acting as prebiotics. The existing
literature does not provide definitive conclusions, but some
human milk oligosaccharides may be considered candidate
prebiotics. Studies have reported that prebiotics containing
Table 2 Attributes of probiotics
 Human origin
 Not a pathogen
 Resistant to technical procedures
 Resistant to gastric acidity
 Capable of adhering to intestinal epithelium
 Capable of colonising the intestinal tract
 Capable of producing antimicrobial substances
 Acts as immunomodulator
 Influences human metabolic activities
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immunoactive oligosaccharides could effectively prevent
atopic dermatitis in low-atopy risk infants and that they
could potentially be used to prevent adolescents becoming
overweight. However, the clinical significance and efficacy
of prebiotics and their possible widespread use in paediatric
practice still needs to be clarified (S67-69).
Synbiotics
Synbiotics are commonly described as a combination of
probiotics and prebiotics in functional food compounds.
Functional food is a food thathasbeenmodifiedandclaims to
improve a person’s health orwell-being by providing benefits
that extend beyond the traditional nutrients it con-
tains. Examples of functional foods include bread, cereals
and drinks that are fortified with vitamins or selected herbs.
They can also contain nutraceuticals, which have physiolog-
ical benefits or provide protection against chronic disease.
Studies have reported that their combined use has
facilitated the survival of live microbial dietary supplements
and their implantation in the gastrointestinal tract (S66–
68). This mechanism has been reported to generate a
Table 3 Use of probiotics in children
Preventing common infections Preventing nosocomial infections Preventing allergies
Preventing antibiotic associated diarrhoea
(AAD)
 Children attending day care cen-
tres during winter months: if pro-
biotics are considered for
preventing upper respiratory tract
infections, only lactobacillus rham-
nosus (LGG) could be considered.
However, evidence is limited and
meta-analyses confirming its
efficacy are lacking.
 Preventing gastrointestinal infec-
tions in day care centres: the use
of probiotics is not supported by
convincing evidence.
 Preventing nosocomial diarrhoea:
if the use of probiotic is consid-
ered, only LGG can be recom-
mended (at least 109 CFU/day for
the duration of their hospital stay).
 Preventing nosocomial respiratory
tract infections: insufficient evi-
dence to recommend probiotics in
these conditions.
 Preventing atopic diseases: based
on the currently available evi-
dence, probiotics cannot be
recommended
 Preventing AAD: LGG or
S. boulardii should be considered.
 Preventing C difficile-associated
diarrhoea: evidence indicates that
S. boulardii can be considered
Notes:
 Other strains of probiotics, on their
own or in combination, are cur-
rently not recommended.
 No safety data are available on the
use of probiotics for preventing
AAD in severely ill children. Their
use in these patients should
undergo special evaluation.
Treating acute gastroenteritis (age)
Treating functional abdominal pain
disorders Preventing and treating infantile colic Safe probiotic use
 LGG and S. boulardii may be
considered as an adjunct to the
oral rehydration therapy. (LGG
should be administered for 5–
7 days, at a dose of
≥1010 CFU/day, while
S. boulardii should be adminis-
tered for 5–7 days, at a dose of
250–750 mg/day)
 No recommendation are currently
available for the use of other
strains or products containing sin-
gle or multiple strains of
probiotics
Note:
 Probiotic administration initiated
early in the course of diarrhoea is
recommended to maximise
results.
Spell out terms in yellow in full please.
 Recommendations for the use of
probiotics in these conditions are
limited by the scarcity of the avail-
able evidence and the lack of
current guidelines.
 A probiotic treatment can be con-
sidered. However, L. reuteri DSM
17938 is the only strain that has
proved to be effective treating
infantile colic in breastfed infants.
(It should be used at a dose of at
least 108 CFU/day for
21–30 days).
Notes:
 Limited evidence on the use of L.
reuteri DSM 17938 in preventing
infantile colic precludes specific
recommendations.
 Insufficient evidence is currently
available for the use of other
strains of probiotics or products
containing probiotic mixtures
 The use of probiotics in children
seems to be safe in general, even
when provided in high doses.
 Probiotics should be used with
caution in special situations, such
as prematurity, immunocompro-
mised patients, critically ill patients,
central venous catheters, cardiac
valvular disease and short-gut syn-
drome.
 Some probiotic strains are not
recommended for children
(namely Enterococcus faecium
SF68), due to the possible transfer
of vanomycin-resistance genes.
 S. boulardii has been effective in
children with C. difficile infections.
However due to the potential for
infections spread, special caution is
required in critically ill patients.
Table 4 Prebiotics selectively used by host microorganisms
 CLA, conjugated linoleic acid





 HMOs, human milk oligosaccharides
 Phenolics and phytochemicals
 Readily fermentable dietary fibres
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beneficial effect in the host organism, by the metabolic
activation of a restricted type of bacteria, which is consid-
ered to be health promoting, and the selective stimulation of
its growth (S69). It has been suggested that these combined
conditions have improved the host’s welfare (S70).
Single products containing an appropriate combination
of probiotics and prebiotics have been reported to guaran-
tee a greater effect than when they have been used
separately. In fact, the synbiotic activity of foods containing
a combination of prebiotics and probiotics is based on their
elective action in two different areas of the gut. Probiotics
are mainly active in the small and large intestine, while
prebiotics are mainly active in the large intestine (S69).
Synbiotics act in combination in two main ways: by
improving the viability of probiotic microorganisms and
by providing specific benefits for the host’s health.
The rationale of using a synbiotic formulation of prebi-
otics is because they function as a selective medium,
favouring the growth of certain probiotic strains, their
fermentation and their intestinal passage. Furthermore,
several studies have reported that prebiotics have positively
influenced the ability of probiotic microorganisms to
develop higher tolerance to particular situations caused by
the presence of possibly challenging conditions. These
include oxygenation and the pH and temperature of the
intestines (S71). In brief, the main reason for using
synbiotics is that the survival of probiotics in the digestive
system is challenging in normal conditions and when an
appropriate prebiotic is not present.
Therefore, using prebiotics to stimulate the effectiveness
of probiotics appears to be a good way of inducing the
beneficial modulation of the metabolic activity of probiotics
in the intestine. At the same time, this preserves the
intestinal biostructure, favours the development and main-
tenance of a beneficial microbiota and inhibits the growth
of potential pathogens in the gut.
In general, the beneficial outcomes of synbiotics for the
host’s health have been related to significant increases in
short-chain fatty acid levels, ketones, carbon disulphides
and methyl acetates. In particular, the potential beneficial
activity of synbiotics in clinical practice has been described
in different clinical conditions (Table 5). The reported
potential therapeutic properties of synbiotics include anti-
carcinogenic, anti-allergic and antibacterial effects (S67). A
few studies, which need to be confirmed or validated, have
also suggested that synbiotics could be used to prevent
constipation, diarrhoea and osteoporosis and in treating
brain diseases associated with altered hepatic function
(S72).
Studies suggest that the synbiotic activity exerted by a
combination of prebiotics and probiotics in functional food
products is mainly due to their ability to modulate the host’s
immune system. This means that they can be used in clinical
practice for selected conditions. It has been reported that
healthcare professionals have used synbiotics in clinical
practice before using antibiotics and surgery interventions
and that their use may be related to cost-effectiveness and
safety considerations. Finally, the availability of synbiotic-
based commercial products is rapidly increasing, due to the
large number of possible existing combinations of prebiotics
and probiotics. This may offer increased therapeutic options
in the near future (S72).
Paraprobiotics and postbiotics
In addition to the factors provided by the host organisms,
further regulatory elements are able to support the main-
tenance and growth of the gut microbiota by favouring
bacterial development, reproduction, protection from exter-
nal insults and intercellular communication (S73). Data
from the literature have emphasised that bacterial viability,
which characterises probiotic activity, is not the exclusive
factor involved in exerting health-promoting effects (S74).
In this regard, the term paraprobiotics is used to identify
nonviable, inactivated microbial cells that have shown
dose-related beneficial effects for consumers. It has been
suggested that paraprobiotics are safer than viable bacterial
products for selected groups of patients, such as individuals
with impaired immune systems, because they pose a
reduced risk of infection, microbial translocation or poten-
tial inflammatory responses. Inactivated bacterial cells are
typically obtained artificially, through chemical or physical
methods such as heating, acid deactivation, freeze-drying,
sonication and ultraviolet treatment. This means that they
are able to modify the cell structure and/or the physiolog-
ical functions of the bacteria while preserving the beneficial
properties of their viable forms (S74).
The term postbiotics describes soluble factors that may be
secreted by viable bacteria or by-products resulting from
bacterial lysis (S73, S74) (Table 6). Several bacterial strains
have shown the ability to express a wide range of soluble
factors of different natures, including cell surface proteins,
vitamins, enzymes, peptides, teichoic acids, plasmalogens
and organic and short-chain fatty acids. These cell-free
supernatant metabolites have been reported to possess
antimicrobial, antioxidant and immunomodulatory proper-
ties. These can positively influence microbiotal homoeosta-
sis as well as the metabolic and/or signalling pathways of
the host organism. The active structure and mechanism of
action that enable postbiotics to produce a beneficial effect
in the context of physiological, immunological, neuro-
Table 5 Activity of synbiotics in humans
 Improving the viability of probiotics
 Expanding Lactobacillus and Bifidobacterium genus counts
 Sustaining immune system modulation abilities in hosting organisms
 Increasing hepatic functions in patients affected by cirrhotic dysfunc-
tions
 Preventing bacterial translocation in individuals in restricted commu-
nities
 Preventing hospital-acquired infections in patients receiving surgery
and/or postoperational procedures
 Reducing risk factors for colon cancer
 Providing preventive effects in selected clinical conditions (namely
osteoporosis, allergic disorders, constipation and diarrhoea)
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hormone biological and metabolic reactions in the host
have not yet been clarified. Investigations are currently in
progress to explain the beneficial health effects of postbiotic
products reported in the literature. These health effects
have been previously been related to their possible anti-
inflammatory, antiproliferative, antioxidant, hypocholes-
terolaemic, antihypertensive, anti-obesogenic, hepatopro-
tective and antimicrobial activities (S74).
The definitions of probiotics and prebiotics have a long
history, particularly with regard to the standing of probi-
otics in international regulations, but there is still no
consensus on their definitions. It is unclear whether these
terms will be maintained or changed in future.
Specific commercial products use fermentation technol-
ogy, such as fermented milk-based infant formulas, and
these can be used in clinical practice to beneficially
modulate the gut microbiota and gut immunity. Selected
lactic acid bacterial strains are used in industrial processes
to ferment cows’ milk, and these are combined with heat
treatment. The end products are formulas that contain no
viable bacteria or prebiotic components, but do contain
specific active factors resulting from the fermentation
process (S75). Metabolites produced through fermentation
processes are used as raw materials for pharmaceutical
products, healthcare supplements and functional foods.
Experimental in vitro and in vivo studies have indicated
that specific fermentation products are involved in estab-
lishing immune balance and oral tolerance, although the
mechanism of action underlying these functions has not yet
been fully explained (S75).
Changes in the microbiome have been documented in
many chronic, mainly immune-mediated, gastrointestinal
and liver diseases and distinct patterns have been associated
with each specific disease. However, causality and the
mechanisms by which the gut microflora influences the
aetiopathogenesis of a disease have not been fully
explained, so they may be considered limiting factors of
this review. Paediatricians are on the frontline when it
comes to caring for children’s health and well-being. The
strength of this review was that we have emphasised the key
roles that paediatricians’ play in minimising preventable
early harmful events that could permanently influence the
composition and/or function of the gut microbiota.
CONCLUSION
The basic science relating to the gut microbiota is changing
rapidly, as clinical data provide evidence of the importance
of diversity in the microbial community and point to the
general accepted role of so-called protective bacteria. Gut
microbes are moving rapidly from being considered poten-
tially dangerous to being considered as a positive influence
on health when they are properly implemented. In clinical
practice, modulation of the gut microbiota may be achieved
by using several approaches, including probiotics, prebi-
otics, synbiotics, paraprobiotics and postbiotics.
A better understanding of the potential impacts of the gut
microbiota on human health, and of the use of related
commercially available products, would lead to more
appropriate use of these products in clinical practice by
healthcare professionals.
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